YOLFTbeta
Fate Therapeutics Inc

Fate Therapeutics Inc

FATE · NASDAQ · Healthcare / Biotechnology

1.28USD-0.06 (-4.48%)

Price History

Full chart

Market Stats

Previous Close1.34
Open1.32
Day Range1.21 – 1.33
52-Week Range0.95 – 3.23
Volume1.81M
Market Cap281.58M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.05
Dividend Yield0.00%
Beta2.55
50-Day Avg2.52
200-Day Avg1.81

About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Bahram Valamehr M.B.A., Ph.D.
  • Employees161
  • Headquarters12278 Scripps Summit Drive, San Diego, CA, United States, 92131, USA
  • Websitehttps://www.fatetherapeutics.com

Leadership

  • Dr. Bahram Valamehr M.B.A., Ph.D.President, CEO & Director · b. 1977
  • Mr. Kamal Adawi M.S., MBACFO & Treasurer · b. 1979
  • Ms. Cindy R. Tahl J.D.Chief Legal & Compliance Officer and Corporate Secretary · b. 1973
  • Ms. Jessica FrancisSenior Vice President of Human Resources & Operations
  • Dr. Martin HoskingHead of Research
  • Dr. Tunde Babalola Ph.D.Senior Vice President of Technical Operations & Quality
  • Mr. Ryan DouglasSenior Director of Investor Relations & Business Development
  • Mr. Andrew HenrySenior Vice President of Clinical Operations · b. 1964
  • Dr. Yu Cai J.D., Ph.D.Head of Intellectual Property & Assistant General Counsel
  • Ms. Kate DuvallCorporate Controller

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.17M2.67M971.00K02.43M4.40M4.11M4.74M10.68M31.43M55.85M96.30M63.53M13.63M6.65M
Growth (%)-+128.21%-63.63%-100.00%-+81.08%-6.72%+15.44%+125.32%+194.33%+77.66%+72.44%-34.03%-78.55%-51.24%
Cost of Revenue13.79M12.00M12.01M16.43M19.86M26.45M34.36M56.02M87.77M125.62M5.85M13.76M157.19M118.53M12.90M
Gross Profit1.17M-9.33M-11.04M-16.43M-17.43M-22.05M-30.25M-51.28M10.68M-94.19M50.00M96.30M-93.65M-104.90M-6.25M
Gross Margin100.00%-349.40%-1136.56%--716.99%-500.91%-736.78%-1081.94%100.00%-299.64%89.52%100.00%-147.41%-769.57%-94.12%
Operating Expense14.46M4.23M6.64M8.47M10.35M9.91M11.87M15.81M111.41M33.90M266.99M404.69M96.86M105.38M141.45M
Operating Income-13.29M-13.56M-17.68M-24.90M-27.78M-31.96M-42.13M-67.09M-100.73M-128.09M-216.99M-308.39M-190.51M-210.28M-147.70M
Operating Margin-1136.15%-507.75%-1820.29%--1142.82%-726.10%-1025.94%-1415.44%-943.14%-407.47%-388.56%-320.23%-299.86%-1542.63%-2222.45%
EBITDA-12.63M-13.16M-19.53M-24.41M-27.09M-30.94M-40.71M-63.70M-94.20M-125.00M-206.30M-294.63M-142.65M-176.58M-127.02M
EBITDA Margin-1079.32%-492.96%-2011.02%--1114.15%-702.95%-991.55%-1343.84%-882.06%-397.65%-369.41%-305.95%-224.52%-1295.41%-1911.22%
Net Income-13.43M-14.24M-20.89M-25.88M-29.99M-33.46M-42.95M-66.60M-98.15M-173.39M-212.15M-255.06M-160.93M-186.26M-136.31M
Net Income Margin-1147.61%-533.30%-2151.80%--1233.73%-760.15%-1046.08%-1405.02%-919.00%-551.59%-379.89%-264.86%-253.30%-1366.46%-2051.08%
R&D9.86M12.00M12.01M16.43M19.86M26.45M34.36M56.02M87.77M125.62M215.52M320.45M172.60M135.00M107.83M
R&D as % of Total Revenue842.56%449.40%1236.56%-816.99%600.91%836.78%1181.94%821.82%399.64%385.92%332.77%271.66%990.40%1622.46%
Interest Expense127.00K487.00K796.00K549.00K2.22M1.64M1.27M1.70M1.75M2.40M4.54M5.84M---
Interest Expense % of Total Revenue10.85%18.24%81.98%-91.32%37.19%30.88%35.78%16.40%7.64%8.13%6.07%---

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.85M11.08M55.58M51.20M67.96M95.05M105.29M213.03M302.27M622.46M921.46M705.56M506.22M440.69M318.94M
Total Liabilities58.53M63.90M4.74M22.86M29.92M21.89M28.10M52.56M57.52M238.01M242.62M221.62M137.80M121.97M111.75M
Total Equity-50.68M-52.83M50.85M28.34M38.04M73.15M77.19M160.47M244.76M384.44M678.84M483.94M368.42M318.73M207.18M
Cash6.39M9.09M54.04M49.10M64.81M88.61M88.95M190.51M99.81M167.35M133.58M61.33M41.87M36.06M46.63M
Total Debt4.84M3.67M1.73M19.63M18.24M10.69M22.06M14.88M26.93M97.30M114.82M109.34M103.54M85.27M77.85M
Net Debt-1.55M-5.41M-52.30M-29.47M-46.57M-77.92M-74.14M-175.63M-72.89M-70.05M-18.77M48.01M61.67M49.21M31.22M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.14M-13.27M-15.37M-22.42M-18.40M-29.82M-36.91M-38.65M-83.17M-39.23M-162.87M-248.21M-132.26M-122.87M-106.08M
Investing Cash Flow200.00K-709.00K-238.00K-882.00K-1.50M-4.11M-10.20M-463.00K-157.45M-161.08M-324.02M166.75M112.67M12.22M111.17M
Financing Cash Flow7.11M16.68M60.56M18.37M35.60M57.74M47.44M140.78M149.93M282.84M453.13M9.21M85.00K99.89M5.49M
Capital Expenditure2.00K709.00K244.00K882.00K1.50M457.00K1.73M2.30M7.39M4.93M50.70M35.57M6.15M730.00K5.95M
Free Cash Flow-12.15M-13.98M-15.62M-23.30M-19.89M-30.28M-38.63M-40.95M-90.57M-44.16M-213.57M-283.77M-138.42M-123.60M-112.04M
Dividends Paid4.40M-00420.00K186.00K15.21M-2.52M------
FCF to OCF100.02%105.34%101.59%103.93%108.14%101.53%104.67%105.96%108.89%112.57%131.13%114.33%104.65%100.59%105.61%
Dividend Paid to FCF-36.22%-0.00%0.00%-2.11%-0.61%-39.36%--2.78%------

Earnings

Report DateNov 13, 2013Mar 17, 2014May 13, 2014Aug 12, 2014Nov 11, 2014Mar 12, 2015May 7, 2015Aug 5, 2015Nov 3, 2015Mar 3, 2016May 9, 2016Aug 8, 2016Nov 7, 2016Mar 16, 2017May 15, 2017Aug 14, 2017Nov 1, 2017Mar 5, 2018May 10, 2018Aug 6, 2018Nov 1, 2018Mar 5, 2019May 7, 2019Aug 6, 2019Nov 5, 2019Mar 2, 2020May 11, 2020Aug 5, 2020Nov 5, 2020Feb 24, 2021May 5, 2021Aug 4, 2021Nov 4, 2021Feb 28, 2022May 4, 2022Aug 3, 2022Nov 3, 2022Feb 28, 2023May 3, 2023Aug 8, 2023Nov 8, 2023Feb 26, 2024May 9, 2024Aug 13, 2024Nov 12, 2024Feb 24, 2025May 13, 2025Aug 12, 2025Nov 13, 2025Feb 26, 2026May 13, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-0.28-0.27-0.32-0.35-0.32-0.31-0.36-0.39-0.32-0.27-0.27-0.31-0.28-0.29-0.20-0.23-0.25-0.24-0.22-0.32-0.28-0.24-0.23-0.31-0.37-0.39-0.39-0.29-0.36-0.39-0.43-0.52-0.55-0.67-0.74-0.81-0.87-0.86-0.62-0.58-0.56-0.52-0.45-0.45-0.41-0.42-0.38-0.34-0.28-0.27-0.28-0.28-0.27
EPS Actual-0.30-0.29-0.34-0.30-0.30-0.30-0.38-0.33-0.24-0.26-0.29-0.29-0.27-0.21-0.24-0.23-0.25-0.29-0.27-0.37-0.31-0.25-0.30-0.36-0.40-0.37-0.44-0.35-0.68-0.61-0.44-0.58-0.45-0.72-0.68-0.78-0.86-0.58-0.19-0.54-0.46-0.45-0.47-0.33-0.40-0.44-0.32-0.29-0.27-0.27-0.26-0.25-
Surprise-7.14%-7.41%-6.25%14.29%6.25%3.23%-5.56%15.38%25.00%3.70%-7.41%6.45%3.57%27.59%-20.00%0.00%0.00%-20.83%-22.73%-15.63%-10.71%-4.17%-30.43%-16.13%-8.11%5.13%-12.82%-20.69%-88.89%-56.41%-2.33%-11.54%18.18%-7.46%8.11%3.70%1.15%32.56%69.35%6.90%17.86%13.46%-4.44%26.67%2.44%-3.82%15.79%14.71%3.57%0.00%7.14%10.71%-
TimingAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap281.58M
Enterprise Value213.67M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales43.38
Price / Book1.90
EPS-1.05
Book Value1.32
Revenue (TTM)6.49M
Gross Profit (TTM)-77.93M
EBITDA-120.50M
Profit Margin0.00%
Operating Margin-1495.39%
Return on Equity-60.75%
Return on Assets-26.22%
Shares Outstanding119.82M
Shares Float105.22M
Beta2.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 12 analystsTarget 5.74
  • Strong Buy
    5
  • Buy
    1
  • Hold
    6

Ownership Breakdown

Institutions
69.05%
Insiders
1.06%
Retail / Other
29.89%

Top Institutional Holders

  • Redmile Group, LLC
    12.87M10.74%
  • BlackRock Inc
    10.07M8.40%
  • Vanguard Capital Management, LLC
    4.19M3.50%
  • Vanguard Portfolio Management, LLC
    4.13M3.45%
  • Acadian Asset Management LLC
    4.12M3.44%
  • Two Sigma Investments LLC
    3.59M3.00%
  • Johnson & Johnson
    3.38M2.82%
  • AQR Capital Management LLC
    3.00M2.50%
  • Renaissance Technologies Corp
    2.97M2.48%
  • Geode Capital Management, LLC
    2.59M2.16%
  • Millennium Management LLC
    2.43M2.03%
  • State Street Corp
    2.26M1.89%
  • UBS Group AG
    1.82M1.52%
  • The Goldman Sachs Group Inc
    1.33M1.11%
  • TANG CAPITAL MANAGEMENT LLC
    1.17M0.97%
  • Citadel Advisors Llc
    993.31K0.83%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.19M2.67%
  • Vanguard Strategic Equity Inv
    3.12M2.61%
  • BlackRock Advantage Small Cap Core Instl
    1.57M1.31%
  • Bruce
    989.19K0.83%